SEC Can't Prove Stock Buyback Scheme, GSK Unit Says

Law360, New York (December 11, 2012, 6:27 PM EST) -- The U.S. Securities and Exchange Commission hasn't identified evidence that Stiefel Laboratories Inc. and its former CEO defrauded investors and employees by repurchasing stock at dramatically undervalued prices before a $2.9 billion sale to GlaxoSmithKline PLC in 2009, Stiefel told a Florida federal judge Monday.

The SEC alleges that between November 2006 and April 2009, Stiefel Labs and its former Chairman and CEO Charles W. Stiefel omitted key information in stock buyback offers to employees and other shareholders that would have alerted them that the price...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Securities and Exchange Commission v. Stiefel Laboratories Inc. et al


Case Number

1:11-cv-24438

Court

Florida Southern

Nature of Suit

Securities/Commodities

Judge

William J. Zloch

Date Filed

December 12, 2011

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.